CTOs on the Move

Barc USA

www.barclab.com

 
Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.barclab.com
  • 5 Delaware Dr Ste [1,...,5]
    New Hyde Park, NY USA 11042
  • Phone: 516.719.1052

Executives

Name Title Contact Details

Similar Companies

SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.

CuraPharm Inc

CuraPharm Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Candel Therapeutics

Also known as Advantagene. Inc., we are a Massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our Gene Mediated Cytotoxic (GMCI™) platform and our rQNestin34.5 platform. GMCI™ is an "off-the-shelf"​ immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.

Cell Therapeutics

Cell Therapeutics, Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kiadis

Kiadis Pharma is a clinical stage biopharmaceutical company focused on developing innovative and potentially life-saving therapies for blood cancer patients where pharmacological standard of care is no longer an alternative. The Company`s main focus is on the development of a cellular therapeutic that will enable partially mismatched donor stem cell transplants from family members in blood cancer patients, thus making them safe and available as the last potentially life saving option. Stem cell transplantation is currently the only potentially curative treatment available for late stage blood cancer patients; however, a standard of care matching donor is only available for half of patients who are progressing with radiation therapy and chemotherapy.